Skip to main content

Table 2 JAK2 p.V617F mutation in nine NSCLCs. Co-occurrence with well-characterized NSCLC oncogenic mutations in KRAS, EGFR, and BRAF are shown

From: Cancer gene profiling in non-small cell lung cancers reveals activating mutations in JAK2 and JAK3 with therapeutic implications

Sample ID Tumor type Tumor cell (%) Sequencing depth (x) JAK2 p.V617F allele fraction (%) Co-occurring mutation (allele fraction %)
592 Non-small cell carcinoma 30 1999 8.2 KRAS p.G12V (17.2)
664 Adenocarcinoma with squamous features 50 1996 7 BRAF p.V600E (27.3)
717 Adenocarcinoma 40 1273 2 -
915 Favoring adenocarcinoma 60 1539 2.1 EGFR exon19 del (52.1)
1182 Adenocarcinoma 40 1997 2.4 BRAF p.V600E (10.4)
1200 Mucinous adenocarcinoma 10 1422 10.5 KRAS p.G12V (4.8)
1527 Adenocarcinoma 30 1997 10.8 -
1588 Adenocarcinoma, acinar type 20 892 6.5 -
1825 Adenocarcinoma with mucinous features 30 1998 13.4 KRAS p.G12C (25.4)